mTOR and regulation of energy homeostasis in humans (Q38113695)

29 August 2017

title

mTOR and regulation of energy homeostasis in humans (English)

1 reference

29 August 2017

4

Maik Gollasch

1 reference

29 August 2017

Marwan Mannaa

1

1 reference

29 August 2017

Stephanie Krämer

series ordinal

2

1 reference

29 August 2017

Michael Boschmann

series ordinal

3

1 reference

29 August 2017

publication date

12 June 2013

1 reference

Journal of Molecular Medicine

29 August 2017

published in

1 reference

29 August 2017

volume

91

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

1167-1175

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-013-1057-6

29 August 2017

exact match

0 references

cites work

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Tuberous sclerosis complex: from Drosophila to human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

TSC2: filling the GAP in the mTOR signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Rapamycin extends maximal lifespan in cancer-prone mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Mediobasal hypothalamic p70 S6 kinase 1 modulates the control of energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Hypothalamic mTOR signaling regulates food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

mTOR tells the brain that the body is hungry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Central nervous system control of food intake and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Post-kidney transplant weight change as marker of poor survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Mechanistic target of rapamycin complex 1 (mTORC1)-mediated phosphorylation is governed by competition between substrates for interaction with raptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

A central role for neuronal AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) in high-protein diet-induced weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Mammalian TOR: a homeostatic ATP sensor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Positional cloning of the mouse obese gene and its human homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Diabetes, obesity, and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Role of cholecystokinin in appetite control and body weight regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Peripheral amylin activates circumventricular organs expressing calcitonin receptor a/b subtypes and receptor-activity modifying proteins in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

A role for ghrelin in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

FGF21 reloaded: challenges of a rapidly growing field

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

AMPK as a mediator of hormonal signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

AMP-activated protein kinase plays a role in the control of food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Globular adiponectin regulates energy homeostasis through AMP-activated protein kinase-acetyl-CoA carboxylase (AMPK/ACC) pathway in the hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Ghrelin in obesity and endocrine diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Brain uptake of intranasally applied radioiodinated leptin in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Leptin transport across the blood-brain barrier: implications for the cause and treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Leptin in human physiology and pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

The role of hypothalamic mammalian target of rapamycin complex 1 signaling in diet-induced obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Effects of the obese gene product on body weight regulation in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Regulation of adipocyte differentiation and insulin action with rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Regulation of ob gene expression and leptin secretion by insulin and dexamethasone in rat adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

AdipoR1 mediates the anorexigenic and insulin/leptin-like actions of adiponectin in the hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Adipokines and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

BetaKlotho is required for metabolic activity of fibroblast growth factor 21

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Cell-specific precursor processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Emerging roles for the transforming growth factor-{beta} superfamily in regulating adiposity and energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Bone morphogenetic proteins and their receptors: potential functions in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Gastrointestinal satiety signals II. Cholecystokinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Sulfated cholecystokinin-8 activates phospho-mTOR immunoreactive neurons of the paraventricular nucleus in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Long-term persistence of hormonal adaptations to weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Metabolic and hemodynamic response of adipose tissue to angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Gender-specific response to interstitial angiotensin II in human white adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Regulation of arterial tone by smooth muscle myosin type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Paracrine role for periadventitial adipose tissue in the regulation of arterial tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Vasodilator signals from perivascular adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Rapamycin attenuates load-induced cardiac hypertrophy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Adiponectin is a novel humoral vasodilator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

The Effect of Oral Glucose Loads on Tissue Metabolism During Angiotensin II Receptor and Beta-receptor Blockade in Obese Hypertensive Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1057-6

Mammalian Target of Rapamycin Pathway Blockade Slows Progression of Diabetic Kidney Disease in Rats

21 January 2018

1 reference

12 December 2020

Hypothalamic gene expression following ghrelin therapy to gastrectomized rodents

1 reference

12 December 2020

Cholecystokinin-58 is the major molecular form in man, dog and cat but not in pig, beef and rat intestine

1 reference

12 December 2020

Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice

1 reference

12 December 2020

Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors

1 reference

12 December 2020

Plasma leptin turnover rates in lean and obese Zucker rats

1 reference

12 December 2020

C-terminal octapeptide of cholecystokinin decreases food intake in man.

1 reference

12 December 2020

Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway

1 reference

12 December 2020

Leptin receptor signaling: pathways to leptin resistance

1 reference

12 December 2020

Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations

1 reference

12 December 2020

Ghrelin: from gene to physiological function

1 reference

12 December 2020

Effect of fasting and leptin deficiency on hypothalamic neuropeptide Y gene transcription in vivo revealed by expression of a lacZ reporter gene

1 reference

12 December 2020

The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33.

1 reference

12 December 2020

The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001.

1 reference

12 December 2020

10.1007/S00109-013-1057-6

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1045867007

0 references

1 reference